Last Price
0.629
Today's Change
+0.006 (0.96%)
Day's Change
0.61 - 0.63
Trading Volume
71,364
Market Cap
24 Million
Shares Outstanding
38 Million
Avg Volume
4,863,158
Avg Price (50 Days)
0.56
Avg Price (200 Days)
2.01
PE Ratio
-0.22
EPS
-2.84
Earnings Announcement
20-Feb-2025
Previous Close
0.62
Open
0.61
Day's Range
0.6099 - 0.6299
Year Range
0.412 - 4.298
Trading Volume
71,455
1 Day Change
0.99%
5 Day Change
0.21%
1 Month Change
-4.64%
3 Month Change
28.43%
6 Month Change
-75.32%
Ytd Change
-78.22%
1 Year Change
-69.30%
3 Year Change
-95.36%
5 Year Change
-96.32%
10 Year Change
-96.32%
Max Change
-96.32%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.